The DOI matches its Crossref record; 1,273 of the 1,273 references it cites were found in a registry or an index.
The c‐myc Promoter: Still MysterY and Challenge
Abstract
The transcription factor c-Myc is a key regulator of cell proliferation, cell growth, differentiation, and apoptosis. Deregulated c-myc expression possesses a high transformation potential and the proto-oncogene c-myc represents a promising target in anticancer therapy. This review on the c-myc promoter describes its organization, the different levels of its normal regulation (including initiation and elongation of transcription, the dual P1/P2 promoters, chromatin structure, c-Myc autosuppression) as well as its deregulation in Burkitt's lymphoma. Furthermore, it summarizes the many different transcription factors, signal transduction pathways, and feedback loops that activate or repress c-myc transcription. Finally, a concept for regulation of the c-myc promoter in different biological settings, for example, immediate-early induction, constant expression throughout the cell cycle in continuously cycling cells, repression during terminal differentiation and deregulation in cancer, is formulated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Moreover, β-catenin has been shown to stimulate c-Myc expression by activating the c-Myc promoter, which comprises multiple T cell factor-4 (TCF-4) binding sites.447”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [447]
Citations
Cites
3 retracted
Opposite Regulation of Myc and p21 Transcription by STAT3 Proteins
Barré, B., Avril, S., & Coqueret, O. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210422200 · Cited by 108
RetractedTong, X., O'Kelly, J., Xie, D., Mori, A., Lemp, N., McKenna, R., Miller, C. W., & Koeffler, H. P. (2004) · Oncogene · doi:10.1038/sj.onc.1207628 · Cited by 86
RetractedGrand, C. L., Powell, T. J., Nagle, R. B., Bearss, D. J., Tye, D., Gleason-Guzman, M. C., & Hurley, L. H. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400460101 · Cited by 55
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756
The language of covalent histone modifications
Strahl, B. D., & Allis, C. D. (2000) · Nature · doi:10.1038/47412 · Cited by 8,679
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature reviews. Cancer · doi:10.1038/nrc839 · Cited by 6,155
Notch Signaling: Cell Fate Control and Signal Integration in Development
Artavanis-Tsakonas, S., Rand, M. D., & Lake, R. J. (1999) · Science · doi:10.1126/science.284.5415.770 · Cited by 5,909
THE NF-κB AND IκB PROTEINS: New Discoveries and Insights
Baldwin, A. S. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.649 · Cited by 5,882
Mechanisms of TGF-β Signaling from Cell Membrane to the Nucleus
Shi, Y., & Massagué, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00432-x · Cited by 5,860
Research works printed but not linked: 3
- Bareket‐Samish, 2000, Signals for TBP/TATA‐box recognition, J. Mol. Biol., 299, 965
- Liu, 2006, Making Myc, Curr. Top. Microbiol. Immunol., 302, 1
- Skokowa, 2006, LEF‐1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia, Nat. Med., 12, 1191, 10.1038/nm1474 · DOI
Cited by
Sorted by citations
Duncan, J. S., Whittle, M. C., Nakamura, K., Abell, A. N., Midland, A. A., Zawistowski, J. S., Johnson, N. L., Granger, D. A., Jordan, N. V., Darr, D. B., et al. (2012) · Cell · doi:10.1016/j.cell.2012.02.053 · Cited by 732
MYC: Connecting selective transcriptional control to global RNA production
Kress, T. R., Sabò, A., & Amati, B. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3984 · Cited by 521
An Overview of MYC and Its Interactome
Conacci-Sorrell, M., McFerrin, L., & Eisenman, R. N. (2014) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a014357 · Cited by 408
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Carabet, L. A., Rennie, P. S., & Cherkasov, A. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms20010120 · Cited by 172
“While being essential for normal Myc regulation in minimizing undesired Myc expression, the integrated biological output from the multiple-input signaling networks poses the risks of driving pathological conditions [33].”
BackgroundInfluentialLiu, O.-G., Xiong, X.-Y., Li, C.-M., Zhou, X.-S., & Li, S.-S. (2018) · Medical Science Monitor · doi:10.12659/msm.905319 · Cited by 4
Metadata
- Authors
- Wierstra, I., & Alves, J.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- Corresponding author
- Inken Wierstra
- Venue
- Advances in Cancer Research
- Publisher
- Elsevier
- Published
- 2008
- Volume
- 99
- Pages
- 113-333
- ISSN
- 0065-230X (ISSN-L)
- OpenAlex
- W1870041030
- Cited by
- 211
- References
- 1,273
- Citations by year
- 2025: 6 · 2024: 5 · 2023: 9 · 2022: 8 · 2021: 9 · 2020: 18 · 2019: 12 · 2018: 11 · 2017: 16 · 2016: 11 · 2015: 9 · 2014: 12 · 2013: 17 · 2012: 13
- FWCI
- 15.49
- Type
- book chapter
- Language
- en
- Open access
- closed
- Locations
- Advances in cancer research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Keywords
- c-Myc, c-myc promoter, transcriptional regulation, chromatin structure, Burkitt lymphoma, proto-oncogenes, signaling pathways, transcription factors, cell cycle, terminal differentiation
- MeSH terms
- Proto-Oncogene Mas, Animals, Burkitt Lymphoma, Chromatin, Gene Expression Regulation, Humans, Neoplasms, Promoter Regions, Genetic, Proto-Oncogenes, Repressor Proteins, Transcription Factors, Signal Transduction, Genes, myc
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
